| Alan Robert Deroy, DPM | |
|
7223 Hanover Pkwy Ste B, Greenbelt, MD 20770-2023 | |
| (301) 441-2655 | |
| (301) 441-2656 |
| Full Name | Alan Robert Deroy |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 23 Years |
| Location | 7223 Hanover Pkwy Ste B, Greenbelt, Maryland |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1184680043 | NPI | - | NPPES |
| 412480400 | Medicaid | MD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 0103300926 (Virginia) | Secondary |
| 213E00000X | Podiatrist | 5901002037 (Michigan) | Secondary |
| 213E00000X | Podiatrist | 01434 (Maryland) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Renaissance Foot And Ankle Center, Pc | 1052360278 | 2 |
News Archive
New insights into Ewing sarcoma, an aggressive childhood cancer, were published July 15 in the prestigious journal Nature. Researchers from the Long School of Medicine at The University of Texas Health Science Center at San Antonio contributed to the study.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
Scientists at the Stanford University School of Medicine have devised a software algorithm that could enable a common laboratory device to virtually separate a whole-blood sample into its different cell types and detect medically important gene-activity changes specific to any one of those cell types.
If a research survey of African American professional women is any indication, attitudes may be changing towards participation in medical research.
› Verified 9 days ago
| Provider Name | Renaissance Foot & Ankle Center, Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1932135951 PECOS PAC ID: 1052360278 Enrollment ID: O20050114000330 |
News Archive
New insights into Ewing sarcoma, an aggressive childhood cancer, were published July 15 in the prestigious journal Nature. Researchers from the Long School of Medicine at The University of Texas Health Science Center at San Antonio contributed to the study.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
Scientists at the Stanford University School of Medicine have devised a software algorithm that could enable a common laboratory device to virtually separate a whole-blood sample into its different cell types and detect medically important gene-activity changes specific to any one of those cell types.
If a research survey of African American professional women is any indication, attitudes may be changing towards participation in medical research.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alan Robert Deroy, DPM 7223 Hanover Pkwy Ste B, Greenbelt, MD 20770-2023 Ph: (301) 441-2655 | Alan Robert Deroy, DPM 7223 Hanover Pkwy Ste B, Greenbelt, MD 20770-2023 Ph: (301) 441-2655 |
News Archive
New insights into Ewing sarcoma, an aggressive childhood cancer, were published July 15 in the prestigious journal Nature. Researchers from the Long School of Medicine at The University of Texas Health Science Center at San Antonio contributed to the study.
Progenics Pharmaceuticals, Inc. today presented the design and rationale of an ongoing phase 1 trial of its prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) therapy at the 2010 Annual Meeting of the American Society of Clinical Oncology (ASCO). This phase 1 trial is assessing the safety, tolerability and initial clinical activity of progressively increasing doses of PSMA ADC in patients with progressive, metastatic, hormone-refractory prostate cancer following prior taxane chemotherapy.
Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.
Scientists at the Stanford University School of Medicine have devised a software algorithm that could enable a common laboratory device to virtually separate a whole-blood sample into its different cell types and detect medically important gene-activity changes specific to any one of those cell types.
If a research survey of African American professional women is any indication, attitudes may be changing towards participation in medical research.
› Verified 9 days ago
Richard S Cohen Dpm Pa Podiatrist Medicare: Medicare Enrolled Practice Location: 7525 Greenway Center Dr, Suite 112, Greenbelt, MD 20770 Phone: 301-345-4087 Fax: 301-345-0482 | |
Urja Shah, Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 7501 Greenway Center Dr Ste 810, Greenbelt, MD 20770 Phone: 301-577-4464 | |
Foot And Ankle Specialists Of The Mid-atlantic, Llc Podiatrist Medicare: Medicare Enrolled Practice Location: 7501 Greenway Center Dr, Suite 810, Greenbelt, MD 20770 Phone: 301-577-4464 | |
Dr. Richard Steven Cohen, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 7525 Greenway Center Dr, Ste 112, Greenbelt, MD 20770 Phone: 301-345-4087 Fax: 301-345-0482 | |
Dr. Gina M. Saffo, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 7501 Greenway Center Dr, Maryland Trade Center Lll, Suite 810, Greenbelt, MD 20770 Phone: 301-577-4464 Fax: 301-577-4702 | |
Dr. Alexander Victor Lakner, DPM Podiatrist Medicare: Medicare Enrolled Practice Location: 7525 Greenway Center Dr Ste 112, Greenbelt, MD 20770 Phone: 301-345-4087 |